These Two Companies Plan To Do A Real-World Evidence Study On Efficacy Of CBG Transdermal Gel On Pain And Inflammation

Avicanna Inc. AVCNF AVCN (FSE:0NN) will be initiating an observational real-world evidence study using RHO Phyto branded Cannabigerol (“CBG”) transdermal gel on patients with musculoskeletal pain and inflammation together with Santé Cannabis, a clinical research site and contract research organization.

Observational Real-World Evidence Study

The research study will seek to enroll 100 patients and evaluate patient-reported efficacy of the RHO Phyto CBG Transdermal Gel containing 2% CBD and 1% CBG on arthritis including osteoarthritis, rheumatoid arthritis, fibromyalgia, muscle and/or joint pain, localized pain, post-surgical pain, muscular and/or structural injuries. The participants, as identified by the healthcare provider will take part in a 3-month study including clinical visits at baseline and 3-month follow-up assessment. In addition to demographic, medical history, medication use and overall symptom assessment questionnaires, the patients will complete the musculoskeletal health questionnaire, a validated measure of symptoms and quality of life.

The study will be conducted by Santé Cannabis, an independent medical cannabis clinic and research services provider. Santé Cannabis has developed a data collection platform and centred model in executing upon its role as a clinical research site and contract research organization. The prospective study is expected to launch in early Q1 2023.

Get your daily dose of cannabis news on Benzinga Cannabis. Don’t miss out on any important developments in the industry.

Photo by Esteban Lopez on Unsplash

Related News

NBA Star Al Harrington Unveils Edibles Inspired By Foods He Enjoyed In 'Grandma's Kitchen'

Avicanna Launches Water-Soluble THC Infuser

Avicanna Secures $627K Via Private Placement